Compounds > ucb 34714
Page last updated: 2024-08-02 09:13:02

ucb 34714

Description

brivaracetam: A pyrrolidinone compound that is used to treat partial onset seizures in adult patients; structure in first source. [MeSH]

brivaracetam : A non-proteinogenic amino acid derivative that is butanamide in which the pro-S hydrogen at position 2 is replaced by a (4R)-2-oxo-4-propylpyrrolidin-1-yl. Used for treatment of partial onset seizures related to epilepsy. [CHeBI]

Cross-References

ID SourceID
PubMed CID9837243
CHEMBL ID607400
SCHEMBL ID122081
CHEBI ID133013
MeSH IDM0462698

Synonyms (54)

Synonym
rikelta
ucb-34714
brivaracetam
2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide
ucb34714
briviact
ucb 34714
CHEBI:133013 ,
(2s)-2-[(4r)-2-oxo-4-propylpyrrolidin-1-yl]butanamide
D08879
brivaracetam (jan/usan/inn)
briviact (tn)
357336-20-0
CHEMBL607400
1-pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphas,4r)-
(2s)-2-((4r)-2-oxo-4-propylpyrrolidin-1-yl)butanamide
brivaracetam [usan:inn]
u863jgg2ia ,
unii-u863jgg2ia
brivaracetam [mart.]
(2s)-2-((4r)-2-oxo-4-propyltetrahydro-1h-pyrrol-1-yl) butanamide
brivaracetam [orange book]
1-pyrrolidineacetamide, .alpha.-ethyl-2-oxo-4-propyl (.alpha.s,4r)-
brivaracetam [inn]
brivaracetam [mi]
brivaracetam [who-dd]
brivaracetam [jan]
brivaracetam [usan]
(2s)-2-((4r)-2-oxo-4-n-propyl-1-pyrrolidinyl)butanamide
MSYKRHVOOPPJKU-BDAKNGLRSA-N
bdbm50422531
SCHEMBL122081
CS-3418
HY-14449
AC-29289
gtpl9041
compound 83alpha
AKOS027324306
mfcd25976668
EX-A2748
DB05541
DTXSID00905081
AS-35277
Q408099
CCG-266666
NCGC00390779-02
(S)-2-((R)-2-OXO-4-PROPYLPYRROLIDIN-1-YL)BUTANAMIDE
BB161996
1-pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphas,4r)-; (alphas,4r)-alpha-ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide; brivaracetam; briviact; ucb 34714
brivaracetamum
brivaracetam (mart.)
1-pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl (alphas,4r)-
n03ax23
ae5 - anti-epileptic drugs 5

Roles (1)

RoleDescription
anticonvulsantA drug used to prevent seizures or reduce their severity.

Drug Classes (2)

ClassDescription
gamma-lactamA lactam in which the amide bond is contained within a five-membered ring, which includes the amide nitrogen and the carbonyl carbon.
non-proteinogenic amino acid derivativeAny derivative of a non-proteinogenic amino acid resulting from reaction at an amino group or carboxy group, or from the replacement of any hydrogen by a heteroatom.

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Synaptic vesicle glycoprotein 2ARattus norvegicus (Norway rat)IC5010,000,000,000,000.0000AID102959

Bioassays (7)

Assay IDTitleYearJournalArticle
AID10673Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
ISSN: 0022-2623		Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity.
AID11197Total clearance at 10 mg/kg was determined in rat2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
ISSN: 0022-2623		Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity.
AID10445Half life at 10 mg/kg was determined in rat2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
ISSN: 0022-2623		Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity.
AID102959In vitro inhibitory activity against [3H](2S)-2-[4-(3-azidophenyl)-2-oxopyrrolidin-1-yl]butanamide binding to levetiracetam binding site2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
ISSN: 0022-2623		Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity.
AID13327Oral bioavailability at 10 mg/kg was determined in rat2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
ISSN: 0022-2623		Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity.
AID113197In vivo dose required to protect 50% audiogenic seizure prone mice against clonic convulsions2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
ISSN: 0022-2623		Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity.
AID1346078Rat synaptic vesicle glycoprotein 2A (Atypical major facilitator superfamily (MSF) proteins)2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
ISSN: 0022-2623		Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity.

Research

Studies (244)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's15 (6.15)29.6817
2010's129 (52.87)24.3611
2020's100 (40.98)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials64 (25.40%)5.53%
Reviews61 (24.21%)6.00%
Case Studies8 (3.17%)4.05%
Observational8 (3.17%)0.25%
Other111 (44.05%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
indoprofen
0
gamma-lactam;
isoindoles;
monocarboxylic acid		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug		00low000000
phthalimidine
0
gamma-lactam;
isoindoles		00low000000
triptolide
0
diterpenoid;
epoxide;
gamma-lactam;
organic heteroheptacyclic compound		antispermatogenic agent;
plant metabolite		00low000000
kt 5823
0
gamma-lactam;
hemiaminal;
indolocarbazole;
methyl ester;
organic heterooctacyclic compound		EC 2.7.11.12 (cGMP-dependent protein kinase) inhibitor00low000000
2-oxindole
0
gamma-lactam;
indolinone		00low000000
kt 5720
0
carboxylic ester;
gamma-lactam;
hemiaminal;
indolocarbazole;
organic heterooctacyclic compound;
semisynthetic derivative;
tertiary alcohol		EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor00low000000
piperlactam s
0
alkaloid;
aromatic ether;
gamma-lactam;
organic heterotetracyclic compound;
phenols		anti-inflammatory agent;
antioxidant;
plant metabolite		00low000000
sf 2370
0
bridged compound;
gamma-lactam;
methyl ester;
organic heterooctacyclic compound		antimicrobial agent;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
tropomyosin-related kinase B receptor antagonist		00low000000
midostaurin
0
benzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound		antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor		00low000000
marizomib
0
beta-lactone;
gamma-lactam;
organic heterobicyclic compound;
organochlorine compound;
salinosporamide		antineoplastic agent;
proteasome inhibitor		00low000000
kt 5926
0
gamma-lactam;
hemiaminal;
indolocarbazole;
methyl ester;
organic heterooctacyclic compound;
tertiary alcohol		EC 2.7.11.18 (myosin-light-chain kinase) inhibitor00low000000
pyranonigrin a
0
cyclic ketone;
enol;
gamma-lactam;
pyranopyrrole;
secondary alcohol		antioxidant;
Aspergillus metabolite;
marine metabolite		00low000000
althiomycin
0
1,3-thiazoles;
aldoxime;
ether;
gamma-lactam;
pentapeptide;
peptide antibiotic;
primary alcohol;
pyrroline;
secondary carboxamide;
tertiary carboxamide		antibacterial agent;
bacterial metabolite;
protein synthesis inhibitor		00low000000
n-nitrososarcosine
0
nitrosamine;
non-proteinogenic amino acid derivative		carcinogenic agent00low000000
3-hydroxynorvaline
0
non-proteinogenic alpha-amino acid;
non-proteinogenic amino acid derivative		00low000000
n'-formylkynurenine
0
amino acid zwitterion;
N-formylkynurenine;
non-proteinogenic amino acid derivative;
non-proteinogenic L-alpha-amino acid		human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		00low000000
ly 404039
0
bridged compound;
dicarboxylic acid;
non-proteinogenic amino acid derivative;
organic heterobicyclic compound;
sulfone		antipsychotic agent;
anxiolytic drug;
dopamine agonist;
metabotropic glutamate receptor agonist		00low000000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
aminooxyacetic acid
0
amino acid;
hydroxylamines;
monocarboxylic acid		anticonvulsant;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor;
EC 4.2.1.22 (cystathionine beta-synthase) inhibitor;
nootropic agent		00low000000
melatonin
0
acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger		00low000000
vanillin
0
benzaldehydes;
monomethoxybenzene;
phenols		anti-inflammatory agent;
anticonvulsant;
antioxidant;
flavouring agent;
plant metabolite		00low000000
tramiprosate
0
amino sulfonic acid;
zwitterion		algal metabolite;
anti-inflammatory agent;
anticonvulsant;
GABA agonist;
nootropic agent		00low000000
phenytoin
0
imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent		00low000000
acetazolamide
0
monocarboxylic acid amide;
sulfonamide;
thiadiazoles		anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor		00low000000
alprazolam
0
organochlorine compound;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic		00low000000
aminoglutethimide
0
dicarboximide;
piperidones;
substituted aniline		adrenergic agent;
anticonvulsant;
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor		00low000000
carbamazepine
0
dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic		00low000000
clobazam
0
1,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
GABA modulator		00low000000
clonazepam
0
1,4-benzodiazepinone;
monochlorobenzenes		anticonvulsant;
anxiolytic drug;
GABA modulator		00low000000
chlorazepate
0
1,4-benzodiazepinoneanticonvulsant;
anxiolytic drug;
GABA modulator;
prodrug		00low000000
nordazepam
0
1,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
GABA modulator;
human metabolite;
sedative		00low000000
diazepam
0
1,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic		00low000000
valproic acid
0
branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent		00low000000
estazolam
0
triazoles;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA modulator		00low000000
ethosuximide
0
dicarboximide;
pyrrolidinone		anticonvulsant;
geroprotector;
T-type calcium channel blocker		00low000000
ethotoin
0
imidazolidine-2,4-dioneanticonvulsant00low000000
felbamate
0
carbamate esteranticonvulsant;
neuroprotective agent		00low000000
flurazepam
0
1,4-benzodiazepinone;
monofluorobenzenes;
organochlorine compound;
tertiary amino compound		anticonvulsant;
anxiolytic drug;
GABAA receptor agonist;
sedative		00low000000
gabapentin
0
gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic		00low000000
lamotrigine
0
1,2,4-triazines;
dichlorobenzene;
primary arylamine		anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic		00low000000
meclofenamic acid
0
aminobenzoic acid;
organochlorine compound;
secondary amino compound		analgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug		00low000000
mephenytoin
0
imidazolidine-2,4-dioneanticonvulsant00low000000
midazolam
0
imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative		00low000000
nimetazepam
0
1,4-benzodiazepinone;
C-nitro compound		anticonvulsant;
antispasmodic drug;
GABA modulator;
sedative		00low000000
nitrazepam
0
1,4-benzodiazepinone;
C-nitro compound		anticonvulsant;
antispasmodic drug;
drug metabolite;
GABA modulator;
sedative		00low000000
palmidrol
0
endocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-(saturated fatty acyl)ethanolamine		anti-inflammatory drug;
anticonvulsant;
antihypertensive agent;
neuroprotective agent		00low000000
phenobarbital
0
barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative		00low000000
prilocaine
0
amino acid amide;
monocarboxylic acid amide		anticonvulsant;
local anaesthetic		00low000000
primidone
0
pyrimidoneanticonvulsant;
environmental contaminant;
xenobiotic		00low000000
propofol
0
phenolsanticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative		00low000000
trimethadione
0
oxazolidinoneanticonvulsant;
geroprotector		00low000000
troglitazone
0
chromanes;
thiazolidinone		anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent		00low000000
vigabatrin
0
gamma-amino acidanticonvulsant;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor		00low000000
zaleplon
0
nitrile;
pyrazolopyrimidine		anticonvulsant;
anxiolytic drug;
central nervous system depressant;
sedative		00low000000
zonisamide
0
1,2-benzoxazoles;
sulfonamide		anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker		00low000000
androsterone
0
17-oxo steroid;
3alpha-hydroxy steroid;
androstanoid;
C19-steroid		androgen;
anticonvulsant;
human blood serum metabolite;
human metabolite;
human urinary metabolite;
mouse metabolite;
pheromone		00low000000
lysine
0
aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite		00low000000
mephobarbital
0
barbituratesanticonvulsant00low000000
paramethadione
0
oxazolidinoneanticonvulsant00low000000
6-methoxybenzoxazolinone
0
aromatic ether;
benzoxazole		antibacterial agent;
anticonvulsant;
antifungal agent;
muscle relaxant;
plant metabolite		00low000000
tricaprylin
0
octanoate ester;
triglyceride		anticonvulsant;
plant metabolite		00low000000
decan-4-olide
0
gamma-lactone;
tetrahydrofuranone		anticonvulsant;
flavouring agent;
food additive		00low000000
magnesium sulfate
0
magnesium salt;
metal sulfate;
organic magnesium salt		anaesthetic;
analgesic;
anti-arrhythmia drug;
anticonvulsant;
calcium channel blocker;
cardiovascular drug;
fertilizer;
tocolytic agent		00low000000
sodium selenate
0
inorganic sodium saltanticonvulsant;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
fertilizer		00low000000
didesethylflurazepam
0
1,4-benzodiazepinone;
monofluorobenzenes;
organochlorine compound;
primary amino compound		anticonvulsant;
anxiolytic drug;
drug metabolite;
GABAA receptor agonist;
sedative		00low000000
oxcarbazepine
0
cyclic ketone;
dibenzoazepine		anticonvulsant;
drug allergen		00low000000
adinazolam
0
triazolobenzodiazepineanticonvulsant;
antidepressant;
anxiolytic drug;
sedative		00low000000
midazolam hydrochloride
0
hydrochloride;
imidazobenzodiazepine		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative		00low000000
mk 458
0
hydrochlorideanticonvulsant;
antiparkinson drug;
dopamine agonist		00low000000
naxagolide
0
organic heterotricyclic compound;
phenols;
tertiary amino compound		anticonvulsant;
antiparkinson drug;
dopamine agonist		00low000000
tiagabine
0
beta-amino acid;
piperidinemonocarboxylic acid;
tertiary amino compound;
thiophenes		anticonvulsant;
GABA reuptake inhibitor		00low000000
pyrrolidine dithiocarbamate
0
dithiocarbamic acids;
pyrrolidines		anticonvulsant;
antineoplastic agent;
geroprotector;
neuroprotective agent;
NF-kappaB inhibitor;
radical scavenger		00low000000
glutaurine
0
dipeptide zwitterion;
dipeptide;
L-glutamine derivative;
sulfonic acid		anticonvulsant;
anxiolytic drug;
hormone;
human metabolite;
mammalian metabolite;
mouse metabolite		00low000000
tiagabine hydrochloride
0
hydrochlorideanticonvulsant;
GABA reuptake inhibitor		00low000000
zofenopril
0
aryl sulfide;
L-proline derivative;
N-acyl-L-amino acid;
thioester		anticonvulsant;
apoptosis inhibitor;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug;
vasodilator agent		00low000000
palmitone
0
dialkyl ketoneanticonvulsant;
metabolite		00low000000
paxilline
0
diterpene alkaloid;
enone;
organic heterohexacyclic compound;
terpenoid indole alkaloid;
tertiary alcohol		anticonvulsant;
Aspergillus metabolite;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
genotoxin;
geroprotector;
mycotoxin;
Penicillium metabolite;
potassium channel blocker		00low000000
10-hydroxycarbamazepine
0
carboxamide;
dibenzoazepine;
ureas		anticonvulsant;
drug allergen;
sodium channel blocker		00low000000
ezogabine
0
carbamate ester;
organofluorine compound;
secondary amino compound;
substituted aniline		anticonvulsant;
potassium channel modulator		00low000000
clorazepate dipotassium
0
potassium saltanticonvulsant;
anxiolytic drug;
GABA modulator;
prodrug		00low000000
eslicarbazepine acetate
0
acetate ester;
carboxamide;
dibenzoazepine;
ureas		anticonvulsant;
drug allergen		00low000000
dizocilpine
0
secondary amino compound;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist		00low000000
carnosine
0
amino acid zwitterion;
dipeptide		anticonvulsant;
antineoplastic agent;
antioxidant;
Daphnia magna metabolite;
geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent		00low000000
solasodine
0
alkaloid antibiotic;
azaspiro compound;
hemiaminal ether;
oxaspiro compound;
sapogenin;
steroid alkaloid		anticonvulsant;
antifungal agent;
antiinfective agent;
antioxidant;
antipyretic;
antispermatogenic agent;
apoptosis inducer;
cardiotonic drug;
central nervous system depressant;
diuretic;
immunomodulator;
plant metabolite;
teratogenic agent		00low000000
L-cycloserine
0
4-amino-1,2-oxazolidin-3-oneanti-HIV agent;
anticonvulsant;
EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor		00low000000
alpha-asarone
0
asaroneanticonvulsant;
GABA modulator		00low000000
thiopental
0
barbituratesanticonvulsant;
drug allergen;
environmental contaminant;
intravenous anaesthetic;
sedative;
xenobiotic		00low000000
zofenoprilate
0
aryl sulfide;
L-proline derivative;
N-acyl-L-amino acid;
thiol		anticonvulsant;
apoptosis inhibitor;
cardioprotective agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
vasodilator agent		00low000000
acacetin
0
dihydroxyflavone;
monomethoxyflavone		anticonvulsant;
plant metabolite		00low000000
hispidulin
0
monomethoxyflavone;
trihydroxyflavone		anti-inflammatory agent;
anticonvulsant;
antineoplastic agent;
antioxidant;
apoptosis inducer;
plant metabolite		00low000000
levetiracetam
0
pyrrolidin-2-onesanticonvulsant;
environmental contaminant;
xenobiotic		00low000000
topiramate
0
cyclic ketal;
ketohexose derivative;
sulfamate ester		anticonvulsant;
sodium channel blocker		00low000000
pregabalin
0
gamma-amino acidanticonvulsant;
calcium channel blocker		00low000000
dizocilpine maleate
0
maleate salt;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist		00low000000
sdz eaa 494
0
monocarboxylic acid;
olefinic compound;
phosphonic acids;
piperazinecarboxylic acid;
tertiary amino compound		anticonvulsant;
neuroprotective agent;
NMDA receptor antagonist		00low000000
ro 25-6981
0
benzenes;
phenols;
piperidines;
secondary alcohol;
tertiary amino compound		anticonvulsant;
antidepressant;
neuroprotective agent;
NMDA receptor antagonist		00low000000
3,3-diethyl-2-pyrrolidinone
0
pyrrolidin-2-onesanticonvulsant;
geroprotector		00low000000
perampanel
0
bipyridines;
nitrile;
pyridone		AMPA receptor antagonist;
anticonvulsant		00low000000
arachidonoylserotonin
0
N-acylserotonin;
phenols		anti-inflammatory agent;
anticonvulsant;
antioxidant;
capsaicin receptor antagonist;
EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor;
human metabolite;
signalling molecule		00low000000
meclofenamate sodium anhydrous
0
hydrateanalgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug		00low000000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
piracetam
1
organonitrogen compound;
organooxygen compound		2004200420.0low000100
levetiracetam
1
pyrrolidin-2-onesanticonvulsant;
environmental contaminant;
xenobiotic		2004200420.0low000100
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
gamma-aminobutyric acid
2
amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule		2007201712.0low000110
carbamates
3
amino-acid anion2007202211.3low000201
phloroglucinol
1
benzenetriol;
phenolic donor		algal metabolite202220222.0low000001
dimethyl sulfoxide
1
sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger		202220222.0low000001
glycine
1
alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical		201720177.0low000010
urea
1
isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		201720177.0low000010
1-anilino-8-naphthalenesulfonate
2
aminonaphthalene;
naphthalenesulfonic acid		fluorescent probe201820214.5low000011
phenytoin
2
imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent		202020213.5low000011
alprazolam
1
organochlorine compound;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic		201820186.0low100010
carbamazepine
11
dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic		201520225.1low700092
carbamazepine epoxide
2
dibenzoazepine;
epoxide;
ureas		allergen;
drug metabolite;
marine xenobiotic metabolite		201920204.5low100020
clobazam
1
1,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
GABA modulator		202120213.0low000001
clonazepam
2
1,4-benzodiazepinone;
monochlorobenzenes		anticonvulsant;
anxiolytic drug;
GABA modulator		201620215.5low100011
diazepam
2
1,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic		201720215.0low000011
valproic acid
4
branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent		201620216.5low300031
gabapentin
2
gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic		2007202010.5low000110
gemfibrozil
1
aromatic etherantilipemic drug2012201212.0low100010
isoflurane
1
organofluorine compoundinhalation anaesthetic202020204.0low000010
lamotrigine
2
1,2,4-triazines;
dichlorobenzene;
primary arylamine		anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic		201820224.0low200011
loratadine
1
benzocycloheptapyridine;
ethyl ester;
N-acylpiperidine;
organochlorine compound;
tertiary carboxamide		anti-allergic agent;
cholinergic antagonist;
geroprotector;
H1-receptor antagonist		201720177.0low000010
lorazepam
4
benzodiazepine201120206.2low200040
losartan
1
biphenylyltetrazole;
imidazoles		angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist		202020204.0low000010
midazolam
1
imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative		201520159.0low100010
phenobarbital
5
barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative		201620215.8low200041
piracetam
24
organonitrogen compound;
organooxygen compound		2004201810.7medium5007170
potassium chloride
1
inorganic chloride;
inorganic potassium salt;
potassium salt		fertilizer2009200915.0low000100
vigabatrin
1
gamma-amino acidanticonvulsant;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor		202020204.0low000010
zonisamide
1
1,2-benzoxazoles;
sulfonamide		anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker		201620168.0low100010
pilocarpine
1
pilocarpineantiglaucoma drug202220222.0low000001
ethinyl estradiol
1
17-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound		xenoestrogen2013201311.0low100010
2,3,4,6-tetrachlorophenol
1
tetrachlorophenolxenobiotic metabolite202220222.0low000001
ethane
1
alkane;
gas molecular entity		plant metabolite;
refrigerant		201620168.0low000010
n-vinyl-2-pyrrolidinone
1
pyrrolidin-2-ones202320231.0low000001
pyrroles
1
pyrrole;
secondary amine		2009200915.0low000100
cyclopentane
1
cycloalkane;
cyclopentanes;
volatile organic compound		non-polar solvent201920195.0low000010
isoxazoles
1
isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		201620168.0low100010
kainic acid
1
dicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid		antinematodal drug;
excitatory amino acid agonist		201820186.0low000010
acetylcysteine
1
acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary		202020204.0low000010
levonorgestrel
1
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin;
synthetic oral contraceptive		2013201311.0low100010
ethambutol
1
ethanolamines;
ethylenediamine derivative		antitubercular agent;
environmental contaminant;
xenobiotic		201920195.0low000010
ethinyl estradiol-norgestrel combination
1
2013201311.0low100010
pregnanolone
1
3-hydroxy-5beta-pregnan-20-one;
3alpha-hydroxy steroid		human metabolite;
intravenous anaesthetic;
sedative		2007200717.0low000100
glutamic acid
2
glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical		201720224.5low000011
oxcarbazepine
3
cyclic ketone;
dibenzoazepine		anticonvulsant;
drug allergen		202020223.3low100021
tiagabine
1
beta-amino acid;
piperidinemonocarboxylic acid;
tertiary amino compound;
thiophenes		anticonvulsant;
GABA reuptake inhibitor		201920195.0low100010
atorvastatin
1
aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic)		environmental contaminant;
xenobiotic		202020204.0low000010
triazoles
3
1,2,3-triazole200720218.3low000111
methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate
1
beta-carbolines202120213.0low000001
1-hydroxymethylmidazolam
1
aromatic primary alcohol;
imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		drug metabolite;
human blood serum metabolite;
human urinary metabolite		201520159.0low100010
fingolimod hydrochloride
1
hydrochlorideimmunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist		202020204.0low000010
ezogabine
1
carbamate ester;
organofluorine compound;
secondary amino compound;
substituted aniline		anticonvulsant;
potassium channel modulator		2007200717.0low000100
rufinamide
2
aromatic amide;
heteroarene		2007202110.0low000101
ly 300164
1
benzodioxoles2007200717.0low000100
eslicarbazepine acetate
5
acetate ester;
carboxamide;
dibenzoazepine;
ureas		anticonvulsant;
drug allergen		201620225.0low000032
lacosamide
10
N-acyl-amino acid200720237.3low000253
alpha-aminobutyric acid
1
alpha-aminobutyric acid;
D-alpha-amino acid		201820186.0low000010
cannabidiol
2
olefinic compound;
phytocannabinoid;
resorcinols		antimicrobial agent;
plant metabolite		201920214.0low000011
D-fructopyranose
2
cyclic hemiketal;
D-fructose;
fructopyranose		sweetening agent2009201611.5low100110
quinine
1
cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic		201720177.0low000010
levetiracetam
54
pyrrolidin-2-onesanticonvulsant;
environmental contaminant;
xenobiotic		200420236.7high120073215
sirolimus
1
antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor		202020204.0low000010
topiramate
5
cyclic ketal;
ketohexose derivative;
sulfamate ester		anticonvulsant;
sodium channel blocker		200920217.2low200131
stiripentol
1
202120213.0low000001
sulfur
1
chalcogen;
nonmetal atom		macronutrient201920195.0low000010
pregabalin
3
gamma-amino acidanticonvulsant;
calcium channel blocker		200720208.3low000120
tetrodotoxin
1
azatetracycloalkane;
oxatetracycloalkane;
quinazoline alkaloid		animal metabolite;
bacterial metabolite;
marine metabolite;
neurotoxin;
voltage-gated sodium channel blocker		2010201014.0low000100
n,n'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine
1
aryl sulfide201920195.0low000010
6 beta-hydroxycortisol
1
11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
6beta-hydroxy steroid;
C21-steroid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mammalian metabolite;
probe		201520159.0low100010
ganaxolone
1
corticosteroid hormone2007200717.0low000100
rwj-333369
1
organochlorine compound2009200915.0low000100
eslicarbazepine
4
dibenzooxazepine201720205.2medium000040
perampanel
13
bipyridines;
nitrile;
pyridone		AMPA receptor antagonist;
anticonvulsant		201620224.8low000094
seletracetam
3
organonitrogen compound;
organooxygen compound		2008201114.3high000210
pimavanserin
1
aromatic ether;
monofluorobenzenes;
piperidines;
tertiary amino compound;
ureas		5-hydroxytryptamine 2A receptor inverse agonist;
antipsychotic agent;
serotonergic antagonist		201720177.0low000010
cariprazine
1
201720177.0low000010
lorcaserin
1
benzazepine;
organochlorine compound		anti-obesity agent;
appetite depressant		201920195.0low000010
losartan potassium
1
202020204.0low000010
ro13-9904
1
202020204.0low000010
suvorexant
1
1,3-benzoxazoles;
aromatic amide;
diazepine;
organochlorine compound;
triazoles		central nervous system depressant;
orexin receptor antagonist		201920195.0low000010
piperidines
1
201720177.0low000010
insulin degludec
1
201720177.0low000010
rifampin
2
cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor		201620225.0low100011
spd 502
1
2009200915.0low000100
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Abdominal Epilepsy0
47
201020226.7low14001406
Abnormalities, Drug-Induced0
1
202020204.0low000010
Absence Seizure0
72
200420235.1medium280054027
Absence Seizure Disorder0
2
201820224.0low100011
Absence Status0
19
200920234.3low3001117
Ache0
1
2008200816.0low000100
Actinic Reticuloid Syndrome0
2
202320231.0low200002
Action Myoclonus-Renal Failure Syndrome0
1
2011201113.0low000010
Acute Brain Injuries0
1
202120213.0low000001
Adolescent Myoclonic Epilepsy0
2
202120232.0low000002
Adverse Drug Event0
7
201720234.0low100043
Age-Related Memory Disorders0
1
202020204.0low000010
Aging0
1
202120213.0low000001
Allergic Encephalomyelitis0
1
202320231.0low000001
Anasarca0
1
202320231.0low000001
Anoxemia0
1
2007200717.0low000100
Anxiety0
1
202020204.0low000010
Apoplexy0
2
202020223.0low000011
Asystole0
1
2007200717.0low000100
Audiogenic Epilepsy0
4
2007202010.5low200130
Aura0
76
200520235.8medium190064525
Autism Spectrum Disorder0
1
201920195.0low000010
Baltic Myoclonic Epilepsy0
2
201620215.5low200011
Behavior Disorders0
6
201520196.2low100060
Benign Infantile Myoclonic Epilepsy0
2
2007202110.0low000101
Benign Psychomotor Epilepsy, Childhood0
1
202020204.0low000010
Bilateral Headache0
1
202120213.0low000001
Brain Injuries0
1
202120213.0low000001
Brain Injuries, Traumatic0
2
202020232.5low000011
Cerebral Palsy0
1
202220222.0low000001
Cerebral Palsy, Athetoid0
1
202220222.0low000001
Chemical Dependence0
1
201920195.0low000010
Child Behavior Disorders0
1
201820186.0low000010
Chronic Disease0
1
202020204.0low000010
Chronic Illness0
1
202020204.0low000010
Cognition Disorders0
2
201120189.5low100020
Complications, Pregnancy0
1
202020204.0low000010
Concussive Convulsion0
4
202020232.5low000013
Convulsions, Grand Mal0
1
201620168.0low100010
Convulsive Generalized Seizure Disorder0
16
201420234.6low2000115
Cramp0
1
202020204.0low000010
Daytime Sleepiness0
1
201620168.0low000010
Deficiency, Mental0
4
201820233.8low000022
Depression0
1
202020204.0low000010
Disease Models, Animal0
9
2007201713.9low000720
Disorders of Excessive Somnolence0
1
201620168.0low000010
Dizziness0
7
201620214.7low300061
Dizzyness0
7
201620214.7low300061
Drug Abuse, Intravenous0
1
202320231.0low000001
Drug Refractory Epilepsy0
21
201520234.3low5000138
Drug-Related Side Effects and Adverse Reactions0
7
201720234.0low100043
Dysesthesia0
1
202020204.0low000010
Dystonia0
1
2008200816.0low000100
Edema0
1
202320231.0low000001
Encephalopathy, Traumatic0
2
202020232.5low000011
Epilepsies, Myoclonic0
2
2007202110.0low000101
Epilepsies, Partial0
47
201020226.7low14001406
Epilepsy1
76
200520235.8medium190064525
Epilepsy Syndromes0
1
201920195.0low000010
Epilepsy, Absence0
2
201820224.0low100011
Epilepsy, Reflex0
4
2007202010.5low200130
Epilepsy, Temporal Lobe0
1
202020204.0low000010
Epilepsy, Tonic-Clonic0
1
201620168.0low100010
Epileptic Syndromes0
1
201920195.0low000010
Epileptiform Neuralgia0
1
202220222.0low000001
Fatigue0
8
201520225.0low200062
Glial Cell Tumors0
1
201720177.0low000010
Glioma0
1
201720177.0low000010
Headache0
1
202120213.0low000001
Heart Arrest0
1
2007200717.0low000100
Hypoxia0
1
2007200717.0low000100
Inflammation0
2
202020232.5low000011
Innate Inflammatory Response0
2
202020232.5low000011
Intellectual Disability0
4
201820233.8low000022
Itching0
1
202020204.0low000010
Kidney Failure0
1
2012201212.0low100010
Lassitude0
8
201520225.0low200062
Lennox Gastaut Syndrome0
1
202120213.0low000001
Lennox-Gastaut Syndrome0
1
202120213.0low000001
Liver Diseases0
1
2013201311.0low100010
Liver Dysfunction0
1
2013201311.0low100010
Local Neoplasm Recurrence0
1
202320231.0low000001
Memory Disorders0
1
202020204.0low000010
Mental Disorders0
6
201520196.2low100060
Muscle Cramp0
1
202020204.0low000010
Nerve Pain0
2
2005202210.5low000101
Neuralgia0
2
2005202210.5low000101
Pain0
1
2008200816.0low000100
Paranoia0
1
202020204.0low000010
Peripheral Nerve Diseases0
1
2008200816.0low000100
Peripheral Nervous System Diseases0
1
2008200816.0low000100
Pregnancy0
3
202020232.7low000012
Pruritus0
1
202020204.0low000010
Renal Insufficiency0
1
2012201212.0low100010
Seizures1
72
200420235.1medium280054027
Sensitivity and Specificity0
1
2008200816.0low000100
Sleepiness0
5
201820214.6low200041
Status Epilepticus0
19
200920234.3low3001117
Stroke0
2
202020223.0low000011
Substance-Related Disorders0
1
201920195.0low000010
Suicidal Ideation0
1
201520159.0low100010
Trigeminal Neuralgia0
1
202220222.0low000001
Unverricht-Lundborg Syndrome1
2
201620215.5low200011

Safety/Toxicity (29)

ArticleYear
Long-term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: An open-label, follow-up trial.
Epilepsia, , Volume: 64, Issue:11		2023
Pharmacokinetics, Safety, and Tolerability of Brivaracetam in Healthy Elderly Participants.
Clinical pharmacology in drug development, , Volume: 12, Issue:11		2023
BRIVEST: A 'real-world' observational, single-centre study investigating the efficacy, safety and tolerability of Brivaracetam.
Epilepsy & behavior : E&B, , Volume: 138		2023
Bioavailability, safety and tolerability of intravenous brivaracetam in healthy Japanese participants.
Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 52, Issue:2		2022
Pharmacokinetics, safety, and tolerability of intravenous brivaracetam in pediatric patients with epilepsy: An open-label trial.
Epilepsia, , Volume: 63, Issue:4		2022
Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review.
Epilepsy & behavior : E&B, , Volume: 118		2021
Long-term safety, efficacy, and quality of life during adjunctive brivaracetam treatment in patients with uncontrolled epilepsy: An open-label follow-up trial.
Epilepsy & behavior : E&B, , Volume: 118		2021
Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial.
Epilepsy research, , Volume: 170		2021
Long-term safety and efficacy of brivaracetam in adults with focal seizures: Results from an open-label, multinational, follow-up trial.
Epilepsy research, , Volume: 166		2020
Time course of drug-related treatment-emergent adverse side effects of brivaracetam.
Epilepsy & behavior : E&B, , Volume: 111		2020
Long-term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11-year, open-label, follow-up trial.
Epilepsia, , Volume: 61, Issue:4		2020
Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis.
Epilepsy & behavior : E&B, , Volume: 103, Issue:Pt A		2020
Safety and tolerability of adjunctive brivaracetam in children with focal seizures: Interim analysis of pooled data from two open-label trials.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, , Volume: 25		2020
Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy.
Epilepsy & behavior : E&B, , Volume: 102		2020
Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients < 16 Years with Epilepsy: An Open-Label Trial.
Paediatric drugs, , Volume: 21, Issue:4		2019
Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis.
Epilepsy & behavior : E&B, , Volume: 80		2018
Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.
Epilepsy & behavior : E&B, , Volume: 79		2018
Comparing Safety and Efficacy of "Third-Generation" Antiepileptic Drugs: Long-Term Extension and Post-marketing Treatment.
CNS drugs, , Volume: 31, Issue:11		2017
Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview.
CNS drugs, , Volume: 31, Issue:2		2017
The adverse event profile of brivaracetam: A meta-analysis of randomized controlled trials.
Seizure, , Volume: 45		2017
Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies.
Epilepsy research, , Volume: 127		2016
Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies.
Epilepsy research, , Volume: 127		2016
Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
Neurology, , Jul-19, Volume: 87, Issue:3		2016
Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures.
Epilepsia, , Volume: 57, Issue:7		2016
Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy.
Epilepsia, , Volume: 57, Issue:7		2016
A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures.
Epilepsia, , Volume: 56, Issue:12		2015
The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies.
Expert opinion on pharmacotherapy, , Volume: 16, Issue:12		2015
The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men.
British journal of clinical pharmacology, , Volume: 66, Issue:1		2008
The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males.
British journal of clinical pharmacology, , Volume: 63, Issue:6		2007

Long-term Use (3)

ArticleYear
Brivaracetam and Levetiracetam Suppress Astroglial L-Glutamate Release through Hemichannel via Inhibition of Synaptic Vesicle Protein.
International journal of molecular sciences, , Apr-19, Volume: 23, Issue:9		2022
Long-term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11-year, open-label, follow-up trial.
Epilepsia, , Volume: 61, Issue:4		2020
BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice.
Acta neurologica Scandinavica, , Volume: 139, Issue:4		2019

Pharmacokinetics (13)

ArticleYear
Pharmacokinetics, Safety, and Tolerability of Brivaracetam in Healthy Elderly Participants.
Clinical pharmacology in drug development, , Volume: 12, Issue:11		2023
Physiologically based pharmacokinetic modeling of brivaracetam and its interactions with rifampin based on CYP2C19 phenotypes.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, , Oct-01, Volume: 177		2022
Efficacy, tolerability and pharmacokinetic variability of brivaracetam in adults with difficult-to-treat epilepsy.
Epilepsy research, , Volume: 183		2022
Pharmacokinetics, safety, and tolerability of intravenous brivaracetam in pediatric patients with epilepsy: An open-label trial.
Epilepsia, , Volume: 63, Issue:4		2022
Pharmacokinetic data on brivaracetam, lacosamide and perampanel during pregnancy and lactation.
Epileptic disorders : international epilepsy journal with videotape, , Apr-01, Volume: 23, Issue:2		2021
Brivaracetam for the treatment of focal-onset seizures: pharmacokinetic and pharmacodynamic evaluations.
Expert opinion on drug metabolism & toxicology, , Volume: 16, Issue:10		2020
Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years.
European journal of clinical pharmacology, , Volume: 73, Issue:6		2017
Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration.
Epilepsy research, , Volume: 128		2016
Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures.
Journal of clinical pharmacology, , Volume: 56, Issue:12		2016
Effect of brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women.
Journal of clinical pharmacology, , Volume: 53, Issue:12		2013
Physiologically based pharmacokinetic/pharmacodynamic animal-to-man prediction of therapeutic dose in a model of epilepsy.
Basic & clinical pharmacology & toxicology, , Volume: 106, Issue:3		2010
The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men.
British journal of clinical pharmacology, , Volume: 66, Issue:1		2008
The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males.
British journal of clinical pharmacology, , Volume: 63, Issue:6		2007

Onset of Action (1)

ArticleYear
Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
Epilepsia, , Volume: 57, Issue:2		2016

Bioavailability (4)

ArticleYear
Design and evaluation of gastro-swelling/gastro-floating sustained-release tablets of brivaracetam for epilepsy therapy.
International journal of pharmaceutics, , Sep-25, Volume: 644		2023
Bioavailability, safety and tolerability of intravenous brivaracetam in healthy Japanese participants.
Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 52, Issue:2		2022
Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus.
Epilepsia, , Volume: 57, Issue:8		2016
Brivaracetam (UCB 34714).
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, , Volume: 4, Issue:1		2007

Dosage (33)

ArticleYear
Real-life evidence about the use of intravenous brivaracetam in urgent seizures: The BRIV-IV study.
Epilepsy & behavior : E&B, , Volume: 147		2023
Retention of brivaracetam in adults with drug-resistant epilepsy at a single tertiary care center.
Epilepsy & behavior : E&B, , Volume: 135		2022
Intravenous Brivaracetam in the Management of Acute Seizures in the Hospital Setting: A Scoping Review.
Journal of intensive care medicine, , Volume: 37, Issue:9		2022
Effect of Number of Previous Antiseizure Medications on Efficacy and Tolerability of Adjunctive Brivaracetam for Uncontrolled Focal Seizures: Post Hoc Analysis.
Advances in therapy, , Volume: 38, Issue:7		2021
Adjunctive brivaracetam - A prospective audit of outcomes from an epilepsy clinic.
Epilepsy & behavior : E&B, , Volume: 116		2021
Long-term safety and efficacy of brivaracetam in adults with focal seizures: Results from an open-label, multinational, follow-up trial.
Epilepsy research, , Volume: 166		2020
Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?
Epilepsia, , Volume: 61, Issue:3		2020
Development and Validation of an UHPLC-MS/MS Assay for the Therapeutic Monitoring of Brivaracetam Plasma Concentrations in Patients with Epilepsy.
Therapeutic drug monitoring, , Volume: 42, Issue:3		2020
Treatment with brivaracetam in children - The experience of a pediatric epilepsy center.
Epilepsy & behavior : E&B, , Volume: 101, Issue:Pt A		2019
Pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with focal seizures: Pooled analysis of data from randomized clinical trials.
Epilepsy research, , Volume: 158		2019
Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients < 16 Years with Epilepsy: An Open-Label Trial.
Paediatric drugs, , Volume: 21, Issue:4		2019
A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.
Epilepsia, , Volume: 60, Issue:5		2019
Intravenous brivaracetam in status epilepticus: Correlation between loading dose, plasma levels and clinical response.
Epilepsy research, , Volume: 149		2019
BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice.
Acta neurologica Scandinavica, , Volume: 139, Issue:4		2019
Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis.
Seizure, , Volume: 61		2018
Brivaracetam-induced elevation of carbamazepine epoxide levels: A post-hoc analysis from the clinical development program.
Epilepsy research, , Volume: 145		2018
Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis.
Epilepsy & behavior : E&B, , Volume: 80		2018
Comparing Safety and Efficacy of "Third-Generation" Antiepileptic Drugs: Long-Term Extension and Post-marketing Treatment.
CNS drugs, , Volume: 31, Issue:11		2017
Evaluation of brivaracetam efficacy as monotherapy in adult patients with focal seizures.
Epilepsy research, , Volume: 137		2017
Extrapolation of a Brivaracetam Exposure-Response Model from Adults to Children with Focal Seizures.
Clinical pharmacokinetics, , Volume: 57, Issue:7		2018
Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years.
European journal of clinical pharmacology, , Volume: 73, Issue:6		2017
Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration.
Epilepsy research, , Volume: 128		2016
Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures.
Journal of clinical pharmacology, , Volume: 56, Issue:12		2016
Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
Epilepsia, , Volume: 57, Issue:2		2016
Adjunctive brivaracetam for patients with refractory partial seizures: A meta-analysis of randomized placebo-controlled trials.
Epilepsy research, , Volume: 114		2015
Brivaracetam and carbamazepine interaction in healthy subjects and in vitro.
Epilepsy research, , Volume: 113		2015
Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype.
Drug metabolism and pharmacokinetics, , Volume: 29, Issue:5		2014
Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
Epilepsia, , Volume: 55, Issue:1		2014
Brivaracetam for the treatment of epilepsy.
Expert opinion on pharmacotherapy, , Volume: 12, Issue:12		2011
Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam.
Epilepsia, , Volume: 52, Issue:2		2011
Physiologically based pharmacokinetic/pharmacodynamic animal-to-man prediction of therapeutic dose in a model of epilepsy.
Basic & clinical pharmacology & toxicology, , Volume: 106, Issue:3		2010
Effect of brivaracetam on cardiac repolarisation--a thorough QT study.
Current medical research and opinion, , Volume: 24, Issue:8		2008
Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:1		2008

Interactions (1)

ArticleYear
A review of the drug-drug interactions of the antiepileptic drug brivaracetam.
Epilepsy research, , Volume: 163		2020